Irinotecán Tarbis (Irinotecan Hydrochloride Trihydrate)

• Irinotecan is used in oncology to target colorectal cancer pathways.
• Metastatic colorectal cancer: improves overall survival when combined with standard chemotherapy regimens.
• Advanced colorectal cancer: reduces tumor progression and may downstage disease.
• Colorectal cancer (first‑line setting): used as part of combination therapy to enhance response rates.

• Irinotecan is a prodrug that is converted intracellularly to SN‑38, a potent inhibitor of topoisomerase I. By stabilizing the DNA‑topoisomerase I complex, it prevents relegation of single‑strand DNA breaks, leading to accumulation of DNA damage, inhibition of DNA replication, and ultimately cancer cell death.

Irinotecan therapy is associated with a range of adverse reactions.

Common Side Effects

• Diarrhea: often delayed and may be severe.
• Nausea and vomiting: typical chemotherapy‑related symptoms.
• Neutropenia: reduced white blood cell count increasing infection risk.
• Fatigue: generalized tiredness during treatment cycles.
• Alopecia: hair loss that may be temporary.
• Abdominal pain: discomfort in the gastrointestinal tract.

Serious or Rare Side Effects

• Severe neutropenic infection: febrile neutropenia requiring urgent care.
• Acute cholinergic syndrome: sweating, salivation, and bronchospasm.
• Severe diarrhea leading to dehydration and electrolyte imbalance.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.
• Allergic reactions: rash, urticaria, or anaphylaxis in rare cases.

• When using Irinotecán Tarbis, clinicians should observe several safety measures.
• Dose adjustment: modify dose in patients with hepatic impairment.
• Monitoring: perform regular complete blood counts to detect neutropenia.
• Hydration: ensure adequate fluid intake to mitigate diarrhea‑related dehydration.
• Drug interactions: avoid concurrent use of strong CYP3A4 inhibitors without dose reduction.
• Pregnancy and lactation: contraindicated unless benefits outweigh potential fetal risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Irinotecan may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase SN‑38 exposure and toxicity.
• CYP3A4 inducers (e.g., rifampin): may reduce efficacy by lowering drug levels.
• Anticholinergic agents: may exacerbate cholinergic syndrome.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): monitor INR due to potential bleeding risk.
• Other myelosuppressive agents: increase risk of severe neutropenia.
• Proton pump inhibitors: may affect gastric pH and drug absorption.